Downregulation of PAR-4, a pro-apoptotic gene, in pancreatic tumors harboring K-ras mutation

Mansoor M. Ahmed, David Sheldon, Mushtaq A. Fruitwala, Kolaparthi Venkatasubbarao, Eun Y. Lee, Seema Gupta, Craig Wood, Mohammed Mohiuddin, William E. Strodel

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Oncogenic ras is known to inhibit cell death and growth inhibitory genes and activate prosurvival genes. Proapoptotic gene PAR-4, has been found to be downregulated by oncogenic ras. Since pancreatic tumors harbor a high incidence of K-ras point mutations, we hypothesized that oncogenic K-ras might influence the function and expression of PAR-4. PAR-4 expression levels were analyzed in 4 established pancreatic tumor cell lines, 10 normal pancreatic tissues, 44 frozen tumor tissues and 25 paraffin-embedded pancreatic adenocarcinoma samples by Real Time RT-PCR, Western blot analysis and immunohistochemistry. K-ras mutational status was analyzed by allele-specific oligonucleotide-hybridization. Expression levels of PAR-4 were correlated with the K-ras mutational status and clinical characteristics. Further, modulation of endogenous PAR-4 was tested by transiently expressing oncogenic ras in a wild-type K-ras pancreatic cancer cell line, BxPC-3. Three cell lines with K-ras mutations showed low levels of PAR-4 when compared to a normal pancreatic tissue. Of 44 frozen tumors, 16 showed appreciable upregulation of Par mRNA and 27 showed significant downregulation of PAR-4 mRNA when compared to normal pancreatic tissue and 1 had levels equivalent to normal pancreatic tissue. Of 25 paraffin-embedded tumors, 9 showed downregulation of PAR-4 protein and this downregulation of PAR-4 correlated significantly with K-ras mutational status (p < 0.00002). In addition, the presence of PAR-4 mRNA or protein expression in pancreatic tumors correlated with prolonged survival. Transient overexpression of oncogenic ras in wild-type K-ras BxPC-3 cells significantly downregulated the endogenous PAR-4 protein levels and conferred accelerated growth. Thus, downregulation or loss of PAR-4 expression by oncogenic ras may provide a selective survival advantage for pancreatic tumors, through inhibition of proapoptotic pathway mediated bv PAR-4.

Original languageEnglish (US)
Pages (from-to)63-70
Number of pages8
JournalInternational Journal of Cancer
Volume122
Issue number1
DOIs
StatePublished - Jan 1 2008
Externally publishedYes

Fingerprint

Down-Regulation
Mutation
Genes
Neoplasms
Paraffin
Messenger RNA
Cell Line
Proteins
Growth
Tumor Cell Line
Pancreatic Neoplasms
Point Mutation
Oligonucleotides
Real-Time Polymerase Chain Reaction
Adenocarcinoma
Cell Death
Up-Regulation
Western Blotting
Immunohistochemistry
Alleles

Keywords

  • K-ras mutation
  • Pancreatic cancer
  • PAR-4
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ahmed, M. M., Sheldon, D., Fruitwala, M. A., Venkatasubbarao, K., Lee, E. Y., Gupta, S., ... Strodel, W. E. (2008). Downregulation of PAR-4, a pro-apoptotic gene, in pancreatic tumors harboring K-ras mutation. International Journal of Cancer, 122(1), 63-70. https://doi.org/10.1002/ijc.23019

Downregulation of PAR-4, a pro-apoptotic gene, in pancreatic tumors harboring K-ras mutation. / Ahmed, Mansoor M.; Sheldon, David; Fruitwala, Mushtaq A.; Venkatasubbarao, Kolaparthi; Lee, Eun Y.; Gupta, Seema; Wood, Craig; Mohiuddin, Mohammed; Strodel, William E.

In: International Journal of Cancer, Vol. 122, No. 1, 01.01.2008, p. 63-70.

Research output: Contribution to journalArticle

Ahmed, MM, Sheldon, D, Fruitwala, MA, Venkatasubbarao, K, Lee, EY, Gupta, S, Wood, C, Mohiuddin, M & Strodel, WE 2008, 'Downregulation of PAR-4, a pro-apoptotic gene, in pancreatic tumors harboring K-ras mutation', International Journal of Cancer, vol. 122, no. 1, pp. 63-70. https://doi.org/10.1002/ijc.23019
Ahmed MM, Sheldon D, Fruitwala MA, Venkatasubbarao K, Lee EY, Gupta S et al. Downregulation of PAR-4, a pro-apoptotic gene, in pancreatic tumors harboring K-ras mutation. International Journal of Cancer. 2008 Jan 1;122(1):63-70. https://doi.org/10.1002/ijc.23019
Ahmed, Mansoor M. ; Sheldon, David ; Fruitwala, Mushtaq A. ; Venkatasubbarao, Kolaparthi ; Lee, Eun Y. ; Gupta, Seema ; Wood, Craig ; Mohiuddin, Mohammed ; Strodel, William E. / Downregulation of PAR-4, a pro-apoptotic gene, in pancreatic tumors harboring K-ras mutation. In: International Journal of Cancer. 2008 ; Vol. 122, No. 1. pp. 63-70.
@article{ff14b60881de439f8de5549e18a72a62,
title = "Downregulation of PAR-4, a pro-apoptotic gene, in pancreatic tumors harboring K-ras mutation",
abstract = "Oncogenic ras is known to inhibit cell death and growth inhibitory genes and activate prosurvival genes. Proapoptotic gene PAR-4, has been found to be downregulated by oncogenic ras. Since pancreatic tumors harbor a high incidence of K-ras point mutations, we hypothesized that oncogenic K-ras might influence the function and expression of PAR-4. PAR-4 expression levels were analyzed in 4 established pancreatic tumor cell lines, 10 normal pancreatic tissues, 44 frozen tumor tissues and 25 paraffin-embedded pancreatic adenocarcinoma samples by Real Time RT-PCR, Western blot analysis and immunohistochemistry. K-ras mutational status was analyzed by allele-specific oligonucleotide-hybridization. Expression levels of PAR-4 were correlated with the K-ras mutational status and clinical characteristics. Further, modulation of endogenous PAR-4 was tested by transiently expressing oncogenic ras in a wild-type K-ras pancreatic cancer cell line, BxPC-3. Three cell lines with K-ras mutations showed low levels of PAR-4 when compared to a normal pancreatic tissue. Of 44 frozen tumors, 16 showed appreciable upregulation of Par mRNA and 27 showed significant downregulation of PAR-4 mRNA when compared to normal pancreatic tissue and 1 had levels equivalent to normal pancreatic tissue. Of 25 paraffin-embedded tumors, 9 showed downregulation of PAR-4 protein and this downregulation of PAR-4 correlated significantly with K-ras mutational status (p < 0.00002). In addition, the presence of PAR-4 mRNA or protein expression in pancreatic tumors correlated with prolonged survival. Transient overexpression of oncogenic ras in wild-type K-ras BxPC-3 cells significantly downregulated the endogenous PAR-4 protein levels and conferred accelerated growth. Thus, downregulation or loss of PAR-4 expression by oncogenic ras may provide a selective survival advantage for pancreatic tumors, through inhibition of proapoptotic pathway mediated bv PAR-4.",
keywords = "K-ras mutation, Pancreatic cancer, PAR-4, Survival",
author = "Ahmed, {Mansoor M.} and David Sheldon and Fruitwala, {Mushtaq A.} and Kolaparthi Venkatasubbarao and Lee, {Eun Y.} and Seema Gupta and Craig Wood and Mohammed Mohiuddin and Strodel, {William E.}",
year = "2008",
month = "1",
day = "1",
doi = "10.1002/ijc.23019",
language = "English (US)",
volume = "122",
pages = "63--70",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Downregulation of PAR-4, a pro-apoptotic gene, in pancreatic tumors harboring K-ras mutation

AU - Ahmed, Mansoor M.

AU - Sheldon, David

AU - Fruitwala, Mushtaq A.

AU - Venkatasubbarao, Kolaparthi

AU - Lee, Eun Y.

AU - Gupta, Seema

AU - Wood, Craig

AU - Mohiuddin, Mohammed

AU - Strodel, William E.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Oncogenic ras is known to inhibit cell death and growth inhibitory genes and activate prosurvival genes. Proapoptotic gene PAR-4, has been found to be downregulated by oncogenic ras. Since pancreatic tumors harbor a high incidence of K-ras point mutations, we hypothesized that oncogenic K-ras might influence the function and expression of PAR-4. PAR-4 expression levels were analyzed in 4 established pancreatic tumor cell lines, 10 normal pancreatic tissues, 44 frozen tumor tissues and 25 paraffin-embedded pancreatic adenocarcinoma samples by Real Time RT-PCR, Western blot analysis and immunohistochemistry. K-ras mutational status was analyzed by allele-specific oligonucleotide-hybridization. Expression levels of PAR-4 were correlated with the K-ras mutational status and clinical characteristics. Further, modulation of endogenous PAR-4 was tested by transiently expressing oncogenic ras in a wild-type K-ras pancreatic cancer cell line, BxPC-3. Three cell lines with K-ras mutations showed low levels of PAR-4 when compared to a normal pancreatic tissue. Of 44 frozen tumors, 16 showed appreciable upregulation of Par mRNA and 27 showed significant downregulation of PAR-4 mRNA when compared to normal pancreatic tissue and 1 had levels equivalent to normal pancreatic tissue. Of 25 paraffin-embedded tumors, 9 showed downregulation of PAR-4 protein and this downregulation of PAR-4 correlated significantly with K-ras mutational status (p < 0.00002). In addition, the presence of PAR-4 mRNA or protein expression in pancreatic tumors correlated with prolonged survival. Transient overexpression of oncogenic ras in wild-type K-ras BxPC-3 cells significantly downregulated the endogenous PAR-4 protein levels and conferred accelerated growth. Thus, downregulation or loss of PAR-4 expression by oncogenic ras may provide a selective survival advantage for pancreatic tumors, through inhibition of proapoptotic pathway mediated bv PAR-4.

AB - Oncogenic ras is known to inhibit cell death and growth inhibitory genes and activate prosurvival genes. Proapoptotic gene PAR-4, has been found to be downregulated by oncogenic ras. Since pancreatic tumors harbor a high incidence of K-ras point mutations, we hypothesized that oncogenic K-ras might influence the function and expression of PAR-4. PAR-4 expression levels were analyzed in 4 established pancreatic tumor cell lines, 10 normal pancreatic tissues, 44 frozen tumor tissues and 25 paraffin-embedded pancreatic adenocarcinoma samples by Real Time RT-PCR, Western blot analysis and immunohistochemistry. K-ras mutational status was analyzed by allele-specific oligonucleotide-hybridization. Expression levels of PAR-4 were correlated with the K-ras mutational status and clinical characteristics. Further, modulation of endogenous PAR-4 was tested by transiently expressing oncogenic ras in a wild-type K-ras pancreatic cancer cell line, BxPC-3. Three cell lines with K-ras mutations showed low levels of PAR-4 when compared to a normal pancreatic tissue. Of 44 frozen tumors, 16 showed appreciable upregulation of Par mRNA and 27 showed significant downregulation of PAR-4 mRNA when compared to normal pancreatic tissue and 1 had levels equivalent to normal pancreatic tissue. Of 25 paraffin-embedded tumors, 9 showed downregulation of PAR-4 protein and this downregulation of PAR-4 correlated significantly with K-ras mutational status (p < 0.00002). In addition, the presence of PAR-4 mRNA or protein expression in pancreatic tumors correlated with prolonged survival. Transient overexpression of oncogenic ras in wild-type K-ras BxPC-3 cells significantly downregulated the endogenous PAR-4 protein levels and conferred accelerated growth. Thus, downregulation or loss of PAR-4 expression by oncogenic ras may provide a selective survival advantage for pancreatic tumors, through inhibition of proapoptotic pathway mediated bv PAR-4.

KW - K-ras mutation

KW - Pancreatic cancer

KW - PAR-4

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=36749017447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36749017447&partnerID=8YFLogxK

U2 - 10.1002/ijc.23019

DO - 10.1002/ijc.23019

M3 - Article

VL - 122

SP - 63

EP - 70

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -